- Home
- MNR vs AGIO Comparison
MNR vs AGIO Comparison
Compare MNR & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNR
- AGIO
- Stock Information
- Founded
- MNR 2017
- AGIO 2007
- Country
- MNR United States
- AGIO United States
- Employees
- MNR N/A
- AGIO N/A
- Industry
- MNR
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- MNR
- AGIO Health Care
- Exchange
- MNR Nasdaq
- AGIO Nasdaq
- Market Cap
- MNR 1.6B
- AGIO 1.4B
- IPO Year
- MNR 2023
- AGIO 2013
- Fundamental
- Price
- MNR $13.31
- AGIO $32.09
- Analyst Decision
- MNR Strong Buy
- AGIO Buy
- Analyst Count
- MNR 3
- AGIO 8
- Target Price
- MNR $24.00
- AGIO $56.00
- AVG Volume (30 Days)
- MNR 315.7K
- AGIO 549.8K
- Earning Date
- MNR 05-08-2025
- AGIO 05-01-2025
- Dividend Yield
- MNR 20.95%
- AGIO N/A
- EPS Growth
- MNR 705.75
- AGIO N/A
- EPS
- MNR 1.56
- AGIO 11.45
- Revenue
- MNR $941,846,000.00
- AGIO $37,035,000.00
- Revenue This Year
- MNR $5.57
- AGIO $27.43
- Revenue Next Year
- MNR N/A
- AGIO $189.81
- P/E Ratio
- MNR $8.52
- AGIO $2.82
- Revenue Growth
- MNR 22.14
- AGIO 25.96
- 52 Week Low
- MNR $12.40
- AGIO $23.42
- 52 Week High
- MNR $20.94
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- MNR 40.08
- AGIO 65.51
- Support Level
- MNR $13.30
- AGIO $29.05
- Resistance Level
- MNR $13.69
- AGIO $30.45
- Average True Range (ATR)
- MNR 0.33
- AGIO 1.13
- MACD
- MNR -0.07
- AGIO 0.33
- Stochastic Oscillator
- MNR 3.56
- AGIO 91.98
About MNR Mach Natural Resources LP
Mach Natural Resources LP is an independent upstream oil and gas company. The company is focused on the acquisition, development and production of oil, natural gas, and NGL reserves in the Anadarko Basin region of Western Oklahoma, Southern Kansas, and the panhandle of Texas.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.